ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue89,91247,15941,09750,561
Cost of Revenue----
Gross Profit89,91247,15941,09750,561
Operating Expenses
Research Development359,613352,360254,970172,181
Selling General and Administrative230,387119,38682,13562,594
Non Recurring----
Others----
Total Operating Expenses590,000471,746337,105234,775
Operating Income or Loss-500,088-424,587-296,008-184,214
Income from Continuing Operations
Total Other Income/Expenses Net9,21414,4795,935-216,390
Earnings Before Interest and Taxes-500,088-424,587-296,008-184,214
Interest Expense-800-1,200-1,200-1,200
Income Before Tax-490,874-410,108-290,073-400,604
Income Tax Expense----40,209
Minority Interest----
Net Income From Continuing Ops-490,874-410,108-290,073-360,395
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-490,874-410,108-290,073-360,395
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-490,874-410,108-290,073-360,395